#Australia #Sydney #TNBC #Kazia Therapeutics #Paxalisib

Kazia Therapeutics Expands Phase 1b Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Limited, a clinical-stage oncology company based in Sydney, has recently made an exciting announcement regarding its ongoing Phase 1b clinical trial focusing on Paxalisib, a potential breakthrough treatment for advanced triple-negative breast cancer (TNBC). With encouraging safety and tolerability data, Kazia has decided to increase its patient enrollment from 12 to 36 participants, reflecting an optimistic outlook on the study's progress.

Expanding the Clinical Trial

The primary aim of expanding the trial is to further assess the safety, tolerability, and initial efficacy of Paxalisib in combination with established treatment regimens involving pembrolizumab and chemotherapy. Such trials are crucial to validate the therapeutic potential of new drugs and to optimize their usage in combating difficult forms of cancer. With an increased cohort, Kazia anticipates gathering more comprehensive data on key metrics such as objective response rate (ORR) and progression-free survival (PFS), along with examining translational biomarkers closely linked to patient outcomes.

Dr. John Friend, CEO of Kazia Therapeutics, expressed encouragement regarding the emerging data from the trial. He highlighted that the expanded enrollment would generate a broader clinical dataset, essential for advancing Paxalisib in treating advanced breast cancer. Notably, the mechanism of Paxalisib— modulating critical resistance pathways—positions it to address issues where existing therapies commonly fail.

A Promising Mechanism of Action

Paxalisib acts as a brain-penetrant inhibitor targeting the PI3K/Akt/mTOR signaling pathway, which plays a significant role in cancer cell growth and survival. By inhibiting this pathway, Paxalisib is expected to alter tumor cell states and improve immune responses, essential features for effective cancer treatment. Additionally, recent preclinical studies published in Molecular Cancer Therapeutics have shown promising results, reinforcing the rationale behind its use in combination therapies for TNBC models.

TNBC is a particularly aggressive form of breast cancer, representing 15 to 20 percent of all breast cancer diagnoses. Patients with TNBC tend to have fewer treatment options and poorer prognoses compared to other breast cancer subtypes, making the success of new therapies like Paxalisib all the more crucial.

Future Directions

Kazia Therapeutics plans to provide further updates on the trial throughout 2026 and into 2027, outlining progress as they analyze more patient data. However, the company made the strategic decision to withdraw its abstracts from a planned presentation at ASCO 2026 primarily to safeguard its intellectual property ahead of imminent filings, a move that sets the stage for productive disclosures in the future.

The combination of Kazia's innovative approach and robust clinical data could reshape treatment pathways for patients suffering from advanced breast cancers. With ongoing trials across various cancer forms, including glioblastoma and brain metastases, Kazia’s initiatives showcase a commitment to redefining oncology's therapeutic landscape.

Kazia Therapeutics does not only focus on Paxalisib; it is also developing additional promising assets like EVT801, a small molecule inhibitor targeting VEGFR3, and other preclinical programs aimed at addressing immunotherapy resistance and metastatic progression. These multidimensional approaches signify Kazia's broader vision of tackling the complexities of cancer treatment.

The trial's expansion is indeed a significant step forward, reinforcing Kazia Therapeutics' position in a challenging and crucial arena of cancer research. As updates unfold, stakeholders and the medical community remain hopeful for groundbreaking advancements that could lead to innovative treatments for some of the most resistant cancer types.